Dental management of von willebrand disease

Replacing VWF by using human plasma-derived viral-inactivated concentrates. For ongoing or severe bleeding DDAVP in responders andor VWF concentrate is recommended.

Assessment Analysis and Associated Dental Management Guidelines The vWF gene is responsible for the making of von Willebrand factor which is made within endothelial cells of blood vessels and the bone marrow cells.

Dental management of von willebrand disease. The dental management of any patient with a bleeding disorder should involve a joint interaction between the patients dentist and haematologist. An established protocol for the management of haemophilia and von Willebrands patients has been established for oral surgical procedures. However Introduction The primary role of haemostasis is to defend the.

A guide for the dental management of the three inherited bleeding disorders von Willebrands disease haemophilia A and haemophilia B was established jointly by the Institute of Medical and Veterinary Science Transfusion and Haemostasis Unit in conjunction with the Medically Compromised Dental Unit at the Adelaide Dental Hospital. This protocol was subjected to a successful trial for 24 months. Pathological functions in health and disease 2.

Von Willebrand disease is a lifelong bleeding disorder in which your blood doesnt clot well. Some people may suspect they have a bleeding disorder when they have heavy bleeding after a dental procedure. Mutations in the von Willebrand disease gene cause von Willebrand disease.

The von Willebrand factor as a blood clotting protein was. Dental issues Bleeding from oral mucosa and epistaxis may be managed with oral or topical tranexamic acid initially. For ongoing or severe bleeding DDAVP in responders andor VWF concentrate is recommended.

Dental extraction Tranexamic acid orally andor mouthwash started preop and continued for 1-5 days. Such as hemophilia A and von Willebrand disease vWD is not straightforward and requires consultation with a hema-tologist10-14 This article will review the literature on recom-mended dental management of patients with inherited bleeding disorders specifically patients with hemophilia A and von Willebrand factor vWF deficiency. A patient with von Willebrands disease presenting for dental treatment requires thorough evaluation prior to the determination of a proper course of treatment.

In this case report a patient with von Willebrands disease presented to the emergency room with dental trauma. A modified treatment plan taking into account the severity of the patients systemic illness and the need for medical management. This study evaluated the effectiveness of a protocol to prevent bleeding after dental extraction in patients with hemophilia von Willebrands disease VWD or platelet disorders.

Replacement therapy was used in cases involving general anesthesia and nerve trunk infiltration was used in patients with severe bleeding disorders severe-to-moderate hemophilia or type 2-3 VWD. There are three subtypes of vWD Table 2 and patients in each subtype may be categorised into mild moderate and severe at the time of diagnosis. Dental management is the same for the equivalent.

Following a dental extraction. He recommends a single dose of factor in cases of severe hemophilia A elevating the factor VIII level to 10IUdL. Desmopressin a synthetic derivative of the hormone vasopressin has been shown to increase factor VIII level in some patients with mild or moderate forms of hemophilia A or type 1 von Willebrand disease.

These guidelines for diagnosis and management of von Willebrand disease VWD were developed for practicing primary care and specialist cliniciansincluding family physicians internists obstetrician-gynecologists pediatricians and nurse-practitionersas well as hematologists and laboratory medicine specialists. MANAGEMENT OF VWD Treatment is aimed at cessation of bleeding or prophylaxis for surgical procedures. Increasing plasma concentration of VWF by releasing endogenous VWF stores through stimulation of endothelial cells with DDAVP.

Replacing VWF by using human plasma-derived viral-inactivated concentrates. Additionally GSD may prolong the patients bleeding time which may necessitate consultation with the treating physician. In the following case our patient required a multidisciplinary approach to address not only her dental needs but also to coordinate the management of both her GSD and an additional complication von Willebrands disease.

This was best achieved in a hospital setting. In the past dental extraction in patients with von Willebrands disease and hemophilia required prolonged hospitalization and transfusion. Replacement therapy with clotting factor concentrates improved this situation 1 but at the risk of viral infections and the formation of factor inhibitors.

2 At the present time recombinant non plasma-derived products reduce this risk. DiseaseMedical Condition VON WILLEBRAND DISEASE also known as von Willebrands disease vWD and VWD contd on next page. Oral management implications contd The dental hygienist should impress upon patientsclients with vWD the importance of good oral hygiene.

DDAVP desmopressin in the dental management of patients with mild or moderate hemophilia and von Willebrands disease. Vierrou AM de la Fuente B Poole AE Hoyer LW. 2938080 PubMed - indexed for MEDLINE MeSH Terms.

Deamino Arginine Vasopressintherapeutic use Dental Care for Disabled. Von Willebrand disease VWD is a common inherited condition that can make you bleed more easily than normal. People with VWD have a low level of a substance called von Willebrand factor in their blood or it does not work very well.

Von Willebrand factor helps blood cells stick together clot when you bleed. If theres not enough of it or it does not work properly it takes longer for. Von Willebrands Disease.

Assessment Analysis and Associated Dental Management Guidelines The vWF gene is responsible for the making of von Willebrand factor which is made within endothelial cells of blood vessels and the bone marrow cells.